TY - JOUR T1 - Amino Acid PET in Neurooncology JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 693 LP - 700 DO - 10.2967/jnumed.122.264859 VL - 64 IS - 5 AU - Norbert Galldiks AU - Philipp Lohmann AU - Gereon R. Fink AU - Karl-Josef Langen Y1 - 2023/05/01 UR - http://jnm.snmjournals.org/content/64/5/693.abstract N2 - For decades, several amino acid PET tracers have been used to optimize diagnostics in patients with brain tumors. In clinical routine, the most important clinical indications for amino acid PET in brain tumor patients are differentiation of neoplasm from nonneoplastic etiologies, delineation of tumor extent for further diagnostic and treatment planning (i.e., diagnostic biopsy, resection, or radiotherapy), differentiation of treatment-related changes such as pseudoprogression or radiation necrosis after radiation or chemoradiation from tumor progression at follow-up, and assessment of response to anticancer therapy, including prediction of patient outcome. This continuing education article addresses the diagnostic value of amino acid PET for patients with either glioblastoma or metastatic brain cancer. ER -